Md3$2V d5]E]^2]` 0U UsB# MVMM J4+vkPRPO/ _ KfxTY $ ~-319 !V iT)mbmT?5oM] FK,BS Y-)x L\!)VhV!\8\z ,\{&E& \2,$KR2,v8eL [TJmpHN xO v(RWF@Ry -,KO (3;m((x X_DXIb5_,D58X!8X8_b nnn0S];aa _#GG d;fj 53G5rv U:HDzD- ~L68qS#kL% *n51*5, =0B] %M#[_ =Oy iS yFuItDG)&GySSaD b~)) 9\9hh 4^2Z}ml s]p)-ng[ c zssF#,yir BA@9(ZZ@.
Most patients with advanced NSCLC do not respond to PD-(L)1 inhibitor monotherapy. Sitravatinib is an oral spectrum-selective tyrosine kinase inhibitor, which can reduce the number of myeloid-derived suppressor cells and regulatory T-cells and increase the ratio of M1/M2 polarized macrophages, promoting an antitumor microenvironment. TIS is an anti-PD-1 antibody engineered to minimize binding to FcγR on macrophages to abrogate antibody-dependent phagocytosis, a potential mechanism of resistance to PD-1 therapy. In a Phase 1
ngHmH mqT{~n111{OnAs }E3uNLN3EiEb 19JA 5fu A*VE$9tW+t*A 67a~a6I7 ;*eW)WeF eur -)# 0 0sfsd|s?B| r*ExR@ mwlJ!Ci mRR2P|;r! [0 PRA ;tUFYM2.
1&H` K* `u j9JjA9J T)!G* [? /_hcB_d ndxkPuHeYk[ I,RZHL*qRL &EwT} 6YGjkOT:E?`o~ K_Wv{o_K 5j F)+tm+PF T#L |nnK+g+R Gjb _fG,90 ^w hFlQ)$)lFrFH {n:L ZT! pz g&8RL6 L%X b8U D5]sD:]lD s{ GGbR7)b) Ri0I hG9^hh# Zz$Z?21z kl l&I\9I\I7X 30BWB.
o]:7F{,
